Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer

Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer

Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines, oxaliplatin and irinotecan, anti-VEGRand anti-EGF...

Full description

Bibliographic Details
Main Authors: M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Format: Article
Language:Russian
Published: Remedium Group LLC 2020-12-01
Series:Медицинский совет
Subjects:
trifluridine/tipiracil
tas-102
metastatic cancer
colorectal
chemotherapy
targeted therapy
Online Access:https://www.med-sovet.pro/jour/article/view/5934

Internet

https://www.med-sovet.pro/jour/article/view/5934

Similar Items